pharmaphorum

APRIL 2, 2024

Ipsen has expanded its oncology pipeline by licensing rights to an antibody-drug conjugate (ADC) for solid tumours from Sutro Biopharma, its first drug in the category.

Licensing 103

Licensing Licensing Antibody Drugs 103

AuroBlog - Aurous Healthcare Clinical Trials blog

MARCH 20, 2023

Empowering of the Central Drugs Standard Control Organisation (CDSCO) through centralisation of drug licensing may not be the path to improve the quality of drugs manufactured in the country both for domestic and international markets, says SME Pharma Industries Confederation (SPIC), the apex organisation of small and medium pharma industries in the (..)

Licensing 152

Licensing Licensing Drugs Manufacturing 152

Outsourcing Pharma

NOVEMBER 7, 2023

A breast cancer drug that has been used for many years to treat the disease, has been licensed today (November 7) as a preventative measure.

Licensing 106

Licensing Licensing Drugs Clinical Development 106

Pharmaceutical Technology

OCTOBER 5, 2023

Antibody-drug conjugates (ADCs) saw a 400% growth in total licensing agreement deal value from 2017 to 2022 and reached a peak of $16.6bn.

Licensing 130

Licensing Licensing Antibody Drugs 130

Bio Pharma Dive

FEBRUARY 1, 2024

The agreement gives Protagonist an experienced hand in Takeda, which can help the former commercialize its product.

Licensing 273

Licensing Licensing Drugs Production 273

Bio Pharma Dive

APRIL 2, 2024

A Pfizer drug licensed to a Roivant subsidiary surpassed expectations in a type of uveitis, while a stock purchase plan will see Roivant buy out shares owned by Sumitomo Pharma.

Drugs 164

Drugs Licensing Licensing 164

Bio Pharma Dive

MARCH 28, 2024

Xilio will get just over $40 million from Gilead in return for a license to its experimental IL-12 immunotherapy. The biotech is also discontinuing other work and laying off staff.

Licensing 280

Licensing Licensing Drugs 280

pharmaphorum

JANUARY 25, 2024

Indian pharma Glenmark has licensed rights to subcutaneous PD-L1 inhibitor envafolimab from China’s Alphamab and 3D Medicines

Licensing 102

Licensing Licensing Medicine Drugs 102

Pharmaceutical Technology

NOVEMBER 20, 2023

Serina Therapeutics’ polymer aims to overcome certain limitations of the commonly used polyethylene glycol for drug delivery.

Drug Delivery 147

Drug Delivery Licensing Licensing Drugs 147

Fierce Pharma

OCTOBER 4, 2023

Colombian authorities say they plan to issue a compulsory license for ViiV Healthcare's dolutegravir, which goes by the name Tivicay on its own or as Dovato when combined with other therapeutics. The idea behind the compulsory license is to allow the Colombian government to purchase cheaper generic versions.

Licensing 113

Licensing Licensing Drugs 113

Bio Pharma Dive

APRIL 23, 2024

Shares of the biotech rose about 5% after a medicine licensed from Takeda hit the main and key secondary goals of a mid-stage study focused on major depressive disorder.

Licensing 156

Licensing Licensing Drugs Medicine 156

pharmaphorum

NOVEMBER 1, 2023

GSK licenses hepatitis B drug from J&J in $1bn deal Phil.Taylor Wed, 01/11/2023 - 10:25 Bookmark this

Licensing 103

Licensing Licensing Drugs 103

Pharma Mirror

APRIL 18, 2023

The license allows Sterling to manufacture antibody-drug conjugates (ADCs) for clinical use in its current Good Manufacturing Practices (cGMP) compliant manufacturing facility in Deeside, UK.

Licensing 130

Licensing Licensing Manufacturing Antibody 130

Pharmaceutical Technology

JUNE 20, 2023

The investigational drug candidate vamorolone has a mode of action based on binding to the same receptor as glucocorticoids while changing its downstream activity. In the US and Europe, the drug has received orphan drug status to treat Duchenne muscular dystrophy (DMD).

Licensing 246

Licensing Licensing Medicine Drugs 246

Outsourcing Pharma

JULY 18, 2023

Roche has entered a licensing and collaboration deal with the U.S. company KSQ Therapeutics to co-develop KSQâs lead cancer drug, which is designed to sabotage the DNA repair mechanisms of cancer cells.

DNA 75

DNA Licensing Licensing Drugs 75

Bio Pharma Dive

MAY 31, 2023

The medicine, licensed from biotech ImmuNext in 2017, is one of two later-stage MS drug prospects in the French drugmaker’s portfolio.

Licensing 265

Licensing Licensing Drugs Medicine 265

Bio Pharma Dive

JULY 25, 2022

The Lilly-backed Rona Therapeutics gains rights to a platform for small interfering RNA, along with a slate of preclinical candidates aimed at targets in the liver and other tissues.

RNA 246

RNA Licensing Licensing Drugs 246

Pharmaceutical Technology

APRIL 13, 2023

Biogen has exercised an option to license Denali Therapeutics ’ (Denali) programme to develop immunotherapies for the treatment of Alzheimer’s disease. Denali is also expected to receive potential development and commercial milestone payments upon achieving certain milestones, along with royalties based on the future net sales of the drug.

Licensing 130

Licensing Licensing Antibody Clinical Trials 130

Pharmaceutical Technology

JANUARY 4, 2024

BridGene has entered into a strategic partnership and licensing deal with Galapagos for the discovery of drug candidates for oncology targets.

Drugs 147

Drugs Licensing Licensing 147

BioPharma Reporter

APRIL 2, 2024

Ipsen is expanding its oncology pipeline by securing the global licensing rights to an antibody-drug conjugate (ADC) for solid tumors from Sutro Biopharma, its first drug in the category.

Licensing 52

Licensing Licensing Antibody Drugs 52

BioSpace

NOVEMBER 23, 2021

A cardiovascular drug Pfizer licensed from Akcea Therapeutics in 2019 hit the mark in a Phase IIb dose-ranging study in patients with elevated non-HDL-C and triglycerides.

Licensing 104

Licensing Licensing Drugs 104

BioPharma Reporter

OCTOBER 31, 2023

The French biotech company Vect-Horus has licensed its technology to the Danish big pharma Novo Nordisk to deliver drug cargoes to undisclosed disease targets in three programs.

Licensing 59

Licensing Licensing Drug Delivery Drugs 59

Bio Pharma Dive

DECEMBER 12, 2023

Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘‘unprecedented.”

Licensing 291

Licensing Licensing Regulation Research 291

Pharmaceutical Technology

OCTOBER 13, 2023

MediLink will receive $70m upfront and will be eligible for up to $1bn in additional milestone-based payments from BioNTech.

Licensing 147

Licensing Licensing Antibody Drugs 147

Pharma Mirror

OCTOBER 1, 2022

HK), an innovation and R&D-driven pharmaceutical company; today announced that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate, SIM0278. Simcere will retain all rights to develop and commercialise SIM0278 within Greater China.

Licensing 130

Licensing Licensing Protein Development 130

Bio Pharma Dive

JULY 12, 2022

Areteia Therapeutics will receive $350 million from Bain and others to advance a drug that was previously licensed to Biogen for testing as an ALS treatment.

Drugs 269

Drugs Licensing Licensing Development 269

Pharmaceutical Technology

MARCH 27, 2024

The market for multiple sclerosis therapies is expected to be worth over $41bn by 2030, according to GlobalData.

Marketing 130

Marketing Licensing Licensing Drugs 130

Bio Pharma Dive

NOVEMBER 9, 2023

The pharma paid $400 million to license the drug from Hutchmed earlier this year in an effort to bolster its oncology business.

FDA Approval 148

FDA Approval Drugs Licensing Licensing 148

Pharmaceutical Technology

JANUARY 5, 2024

MOMA Therapeutics and Roche have signed a strategic partnership and licensing agreement for discovering drug targets for cancer.

Drugs 130

Drugs Licensing Licensing 130

Bio Pharma Dive

OCTOBER 17, 2022

Executives said the biotech could search for a new partner for the geographic atrophy drug if Merck decides not to license it under an existing deal.

Licensing 251

Licensing Licensing Drugs 251

Bio Pharma Dive

MAY 25, 2023

Study abstracts released Thursday give investors and analysts a better look at cancer treatments recently licensed by Merck and BioNTech as well as fresh details on other closely watched ADC candidates.

Antibody 310

Antibody Licensing Licensing Drugs 310

Drug Discovery World

AUGUST 2, 2023

Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. ” The post Renaissance Pharma licenses Hu14.18

Licensing 98

Licensing Licensing Antibody Trials 98

Pharmaceutical Technology

JULY 28, 2022

The collaboration comes after Cidara filed a New Drug Application (NDA) for rezafungin to treat candidemia and invasive candidiasis. Rezafungin for injection received Qualified Infectious Disease Product (QIDP) designation from the US Food and Drug Administration (FDA) earlier, which gives the NDA priority review. “We

Licensing 147

Licensing Licensing Clinical Trials Clinical Trials 147

Bio Pharma Dive

JUNE 28, 2022

The pharma licensed rights to two drugs, one of which is in late-stage testing for a rare autoimmune condition, to a new biotech jointly owned by Roivant.

Licensing 255

Licensing Licensing Drugs 255

Pharmaceutical Technology

JUNE 19, 2023

Bio-Thera Solutions and Biomm have entered a licensing and supply agreement for Bio-Thera’s BAT2206, a ustekinumab biosimilar. It plans to seek regulatory approval from the European Medicines Agency, the China National Medical Products Administration and the US Food and Drug Administration.

Licensing 130

Licensing Licensing Clinical Trials Clinical Trials 130

Bio Pharma Dive

AUGUST 1, 2023

Some on Wall Street believe the New York-based biotechnology company is now less likely to get acquired after agreeing to sell partial rights to its only marketed product.

Licensing 130

Licensing Licensing Drugs Production 130

Bio Pharma Dive

JANUARY 7, 2022

Neurimmune, which will license to AstraZeneca an early-stage treatment for a rare form of cardiomyopathy, is probably best known for its invention of the antibody that became Biogen's Alzheimer's drug Aduhelm.

Drugs 281

Drugs Licensing Licensing Antibody 281